Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1395
- Registration Number
- NCT00048074
MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1609
- Registration Number
- NCT00048061
Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00048009
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT00048035
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT00048126
Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00048022
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00048139
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT00048048
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.
Not Applicable
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002256
- Locations
- 🇺🇸
Hoffmann - La Roche Inc, Nutley, New Jersey, United States
A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
Not Applicable
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT00002034
- Locations
- 🇺🇸
Dr Alfred F Burnside Jr, Columbia, South Carolina, United States
🇺🇸SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
🇨🇦Southern Alberta HIV Clinic / Foothills Hosp, Calgary, Alberta, Canada
© Copyright 2024. All Rights Reserved by MedPath